Key Drivers
- Cash Conversion
- Manageable Leverage
- Full Valuation
AIAI Summary
Smith & Nephew has shifted from a defensive medtech compounder to a “prove-it” turnaround where the real investment case now hinges on RISE delivering sustained margin expansion and converting CORI XT/LEAF/REGENETEN momentum into measurable earnings, because at 23.2x earnings the stock has limited room for another execution miss even though cash flow and buybacks still provide downside support.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Conversion
- •Manageable Leverage
- •Full Valuation
SNN is a profitable, cash-generative business with solid liquidity and manageable leverage, but its full valuation and intangible-heavy balance sheet limit near-term upside.
Price Behavior
Key Price Behavior Insights:
- •Hold $29
- •Reclaim $30+
- •Break resistance
SNN has staged a tentative bounce back above $30, but it remains fragile and must hold $29 while reclaiming $30.6–$31.3 to signal a durable recovery.
Brief drop to a 21-day low near $28.73 followed by a rebound to $30.25 signals a defensive bounce, not yet a confirmed trend reversal
Sentiment & News
Key News Insights:
- •Revenue growth
- •CORI traction
- •RISE reset
Smith & Nephew is showing improving recovery with stronger 2026 growth, a $500 million buyback, and promising CORI robotics traction, while launching RISE after mixed prior margin performance.
The update is modestly positive for SNN, as better operating momentum and shareholder returns outweigh lingering margin-execution concerns
Similar Companies in Healthcare
Other companies in the same sector with AI ratings